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Abstract
Background:  Searching for novel molecular markers that dependably predict or indicate
responses of human cancer cells to epidermal growth factor receptor (EGFR)-targeted therapy is
strongly warranted. The purpose of the current study was to evaluate hypoxia-inducible factor-1α
(HIF-1α) as a novel response marker compared with previously explored markers following
treatment with an EGFR-blocking monoclonal antibody (cetuximab) and a small-molecule EGFR
tyrosine kinase inhibitor (gefitinib) in a group of cancer cell lines containing wild-type or tyrosine
kinase domain-mutated EGFR.
Results: We found that, compared with previously studied response markers, including EGFR per
se and three EGFR downstream signal molecules (ERK, Akt, and STAT3), which showed variable
post-treatment changes in levels of phosphorylation and no consistent link of the changes to
therapeutic responses, HIF-1α showed a selective decrease in protein levels only in responsive cell
lines. To demonstrate a critical role of HIF-1α downregulation by EGFR-targeted treatment, we
introduced a constitutively expressed HIF-1α mutant (HIF-1α/∆ODD) that is resistant to
cetuximab-induced downregulation in a cetuximab-responsive cell line (A431); we found that the
HIF-1α/∆ODD-transfected cells remained sensitive to cetuximab-induced inhibition of Akt and
ERK phosphorylation but were remarkably less responsive to cetuximab-induced growth inhibition
compared with corresponding control cells.
Conclusion:  Our data indicates that downregulation of HIF-1α is associated with positive
therapeutic responses of cancer cells to EGFR-targeted therapy and suggest further investigation
using HIF-1α as an indicator of tumor response to EGFR-targeted therapy in preclinical studies and
in the clinical setting.
Background
Epidermal growth factor receptor (EGFR) has been impli-
cated in the development and progression of a diverse
type of solid tumors. Over the past two decades, experi-
mental cancer therapies targeting EGFR have been studied
extensively [1-4]. Recent clinical studies have found that
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targeting EGFR with receptor-blocking monoclonal anti-
bodies such as cetuximab and panitumumab, or with
small-molecule EGFR tyrosine kinase inhibitors (TKIs)
such as gefitinib and erlotinib, is effective against several
types of solid tumors [5-9]. TKI is particularly effective
against a subset of non-small cell lung cancers (NSCLCs)
that have several somatic mutations in the EGFR tyrosine
kinase domain [10-12]. However, many patients do not
experience favorable responses to EGFR-targeted therapy,
regardless of positive or even high EGFR expression in
their tumors [5-9].
Accumulating evidence indicates that the response of can-
cer cells to EGFR-targeted therapy is a complex process
that can be affected by multiple intrinsic and extrinsic
resistance mechanisms. Currently, there is a lack of
dependable response markers that can objectively predict
or indicate therapeutic responses of patients to EGFR-tar-
geted therapies. Exploration of the genetic and biochemi-
cal determinants of response to the therapy not only may
help identifying patients who would benefit from EGFR-
targeted therapy but also may help in the design of co-tar-
geting strategies to improve treatment effectiveness in
patients who do not experience an optimal response to
EGFR-targeted therapy alone.
We and others recently found that treatment of responsive
cancer cells with cetuximab or gefitinib downregulated
the levels of hypoxia-inducible factor-1α (HIF-1α) under
both normoxic and hypoxic conditions [13,14]. HIF-1α is
a component of the HIF-1 heterodimer that is an impor-
tant transcription factor for the expression of a wide array
of genes involved in a variety of cellular functions, includ-
ing cell cycle traversal, angiogenesis, anti-apoptotic activ-
ity, and oxygen homeostasis [15,16]. HIF-1α is
overexpressed in a large number of human tumors, and its
overexpression correlates with poor prognosis and treat-
ment failure [15,16]. HIF-1α has a very quick turnover
rate in normoxia due to an oxygen-dependent ubiquitina-
tion and degradation process of the protein [15,16] and is
thus constantly replenished by newly synthesized protein
in a phosphatidylinositol 3-kinase signaling pathway-
dependent manner that may be activated by multiple
growth factors or oncogenes [17-22]. This existing knowl-
edge suggests that HIF-1α may be a good indicator of
tumor response to EGFR-targeted therapy, but to date no
studies have investigated this possibility.
In the present study, we used a group of cancer cell lines
with overexpressed EGFR or tyrosine kinase domain-
mutated EGFR to determine the association of the cellular
responses with response markers to EGFR-targeted ther-
apy with cetuximab and gefitinib. Two recent studies eval-
uated biochemical changes in cell signaling after
cetuximab and gefitinib treatment in association with
therapeutic responses of several EGFR wild-type and tyro-
sine kinase domain-mutated cancer cell lines [23,24].
Amann et al. found that both agents induced apoptosis in
HCC827 cells (an NSCLC cell line with a 746E-750A in-
frame deletion) and that the IC50 (50% inhibitory con-
centrations) of TKIs and cetuximab were more closely
associated with the phosphorylation inhibition of extra-
cellular signaling-related kinase (ERK) and Akt than with
EGFR in HCC827, H1819, and H1299 cell lines [23].
Mukohara et al. found that gefitinib and cetuximab had
similar effects on inhibiting the growth of NSCLC cells
with wild-type EGFR (slight inhibition in A549 and H441
cells and moderate inhibition in H1666 cells) but that
gefitinib was stronger than cetuximab in inhibiting EGFR-
mutated cell lines (H3255, DFCILU-011, and PC-9). In
HCC827 cells, both gefitinib and cetuximab induced
apoptosis, but gefitinib induced apoptosis to a greater
extent than cetuximab [24].
We found in this study that post-treatment downregula-
tion of HIF-1α was more consistently associated with cel-
lular response than were the biochemical changes of ERK
and Akt or that of STAT3, another downstream signaling
molecule commonly activated by EGFR. When we experi-
mentally elevated HIF-1α expression level by transfecting
a constitutively expressed HIF-1α mutant in A431 cells,
we found marked resistance of the transfected cells to
cetuximab treatment, despite their unchanged sensitivity
to cetuximab-induced inhibition of ERK and Akt phos-
phorylation levels. Our data suggest that HIF-1α is an
effective molecular response marker for EGFR-targeted
therapy and should be further tested in preclinical studies
and in clinical trials.
Results
Time- and dose-dependent anti-proliferative and 
apoptotic responses of cancer cells with wild-type and 
tyrosine kinase domain-mutated EGFR to cetuximab and 
gefitinib treatment
Figure 1 shows the genetic and biochemical characteristics
of the cell lines used in our study. Compared with the
EGFR coding sequences in the GenBank, which originated
from A431 cells, no mutations were found in the tyrosine
kinase domain of EGFR in DiFi colorectal carcinoma cells
(Fig. 1a). In contrast, HCC827 and HCC2279 NSCLC cells
had a ∆E746-A750 deletion mutation, and H3255 and
H1975 cells had an L858R point mutation. Figure 1b
shows the levels of protein expression in the EGFR family,
including EGFR (HER1), HER2, and HER3, and the levels
of activation-specific phosphorylation of the three most
common EGFR substrates, ERK, Akt, and STAT3. At base-
line, HCC827, HCC2279, and H3255 cells expressed
intermediate levels of EGFR, whereas A431 and DiFi cells
expressed high levels. In contrast, H1975 cells expressed
the lowest level of EGFR, which was barely detectableMolecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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unless the film was overexposed. HER2 and HER3 were
readily detectable in the cell lines except in H3255 cells
(low in HER3) and HCC2279 cells (low in both HER2
and HER3). The basal levels of EGFR downstream signal-
ing, shown by the levels of activation-specific phosphor-
ylation of Akt, ERK, and STAT3, were not consistently
associated with the HER family expression levels or EGFR
sequence-coding status in a positive or negative manner
among the cell lines.
Figure 2a shows the time-dependent responses of these
individual cell lines to treatment with 10 nM cetuximab or
0.5 µM gefitinib for 4 days. Four cell lines (DiFi, HCC827,
H3255, and A431) showed marked growth inhibition
responses after cetuximab or gefitinib treatment, whereas
HCC2279 and H1975 cells showed only moderate or
poor growth inhibition. The degrees of growth inhibition
of DiFi cells after cetuximab (10 nM) and gefitinib (0.5
µM) treatments were comparable, but in A431 and
HCC827 cells more growth inhibition was induced by
cetuximab than by gefitinib. In contrast, H3255 cells
responded more strongly to gefitinib than to cetuximab:
massive cell death was microscopically visible just a few
hours after exposure to gefitinib, whereas the response of
H3255 cells to cetuximab was slower and not evident
until those cells had been exposed to the treatment over-
night (data not shown). HCC2279 and H1975 cell lines
demonstrated much less growth inhibition than did other
cell lines in response to treatment with either agent. The
growth rate of HCC2279 cells was much slower than that
in the other cell lines, which may partly explain the mod-
erate inhibitory effects of the agents on HCC2279 cell pro-
liferation. H1975 cells, which also contain a second
mutation (T790M) linked to gefitinib resistance [25],
responded poorly to either agent.
Cancer cell lines with wild-type or tyrosine kinase domain-mutated EGFR Figure 1
Cancer cell lines with wild-type or tyrosine kinase domain-mutated EGFR. (a) PCR fragments from the indicated cell lines were 
compared with the wild-type sequence of EGFR. The black arrows indicate the codons E746 to A750, which are present in the 
EGFR in DiFi cells but have been deleted in HCC827 and HCC2279 cells. Codon L858R substitution in H1975 and H3255 cells 
is indicated by arrows. (b) Lysates from the indicated cell lines maintained in regular culture medium were prepared for West-
ern blot analysis using antibodies directed against EGFR, HER2, and HER3, and antibodies directed against total and activation-
specific phosphorylated downstream signaling molecules (ERK, Akt, and STAT3). The level of β-actin was used as a reference 
of lysate protein loading control of each cell line.Molecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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Figure 2b shows the simultaneous dose-dependent
growth inhibition responses of the cell lines to treatment
with serial dilutions of cetuximab for 72 hours. H3255
cells showed a dose-dependent response to cetuximab
that was similar to that of DiFi cells, and HCC827 cells
showed a response that was less sensitive than that of DiFi
cells but better than that of A431 cells at lower doses (~3
nM). The growth of HCC2279 and H1975 cells was min-
imally inhibited by cetuximab.
In contrast to the results of cetuximab treatment, two
EGFR-mutated cell lines, HCC827 and H3255, were far
more sensitive to lower (<0.01 µM) concentrations of
gefitinib than were DiFi and A431 cells (Fig. 2c). When
the gefitinib concentration was ≥ 0.1 µM, DiFi cells exhib-
ited responses comparable to those seen in HCC827 and
H3255 cells, but this concentration was still lower than
the doses required to produce similar growth inhibition
in A431 cells. HCC2279 cells also responded to gefitinib
treatment at lower concentrations compared with DiFi
and A431 cells, but the maximal level of inhibition was
less than that seen in DiFi and A431 cells. Unlike other
cells, H1975 cells responded poorly to gefitinib, as
reported by other investigators [25].
Dose- and time-dependent responses of wild-type EGFR and tyrosine kinase domain-mutated EGFR cells to cetuximab and  gefitinib treatment Figure 2
Dose- and time-dependent responses of wild-type EGFR and tyrosine kinase domain-mutated EGFR cells to cetuximab and 
gefitinib treatment. (a) Absolute cell numbers in each treatment group (control [DMSO]), 5 nM cetuximab, and 0.5 µM gefit-
inib, all in 0.5% FBS medium) were plotted against the duration of treatment. (b) The inhibition of cell proliferation after treat-
ment with cetuximab was measured by an MTT assay and is shown as a percentage of the optical density value of control cells 
(untreated) for each concentration tested. (c) The inhibition of cell proliferation after treatment with gefitinib was measured as 
in (b) and is shown as a percentage of the optical density value of vehicle-treated cells (DMSO) for each concentration tested. 
Results are shown as the mean of five independent measurements, plus or minus the standard deviation (SD). The magnitude 
of some SDs was smaller than the symbol size; thus some bars do not appear in the figure.Molecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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To determine whether cetuximab or gefitinib induced
apoptosis in the cell lines, we used two independent
apoptosis assays: an enzyme-linked immunosorbent
assay to measure the cytoplasmic levels of histone-associ-
ated DNA fragments characteristic of apoptotic cells and a
Western blot analysis to detect the proteolytic cleavage of
poly(adenosine diphosphate-ribose) polymerase (PARP)
(Fig. 3a and 3b). Clear evidence of apoptosis was found in
three cell lines: DiFi, HCC827, and H3255. At the doses
tested, gefitinib seemed to induce a higher cytoplasmic
level of histone-associated DNA fragments than did cetux-
imab (Fig. 3a), but both agents had similar effects on
PARP cleavage (Fig. 3b). DiFi cells contained a high basal
level of cleaved PARP when cultured in low-serum
medium, but the cleaved PARP fragment level clearly
increased after treatment. Although cell proliferation was
strongly inhibited, no clear sign of apoptosis was detected
in A431 cells after treatment with cetuximab or gefitinib
under the treatment condition consisting of 0.5% FBS in
culture medium. As expected, HCC2279 and H1975 cells
showed modest or poor anti-proliferative responses to the
treatments, with no apoptosis detected in these cell lines
with either treatment.
Lack of consistency of changes in phosphorylation levels of 
EGFR and common EGFR substrates in association with 
positive response to cetuximab and gefitinib treatment
Following demonstration of their responses to cetuximab
and gefitinib treatment, we next used this group of cell
lines to assess the levels of association between growth
inhibition response after treatment with cetuximab or
gefitinib and the changes in phosphorylation levels of
EGFR and common EGFR substrates. Overnight incuba-
tion with cetuximab downregulated total EGFR contents
by various degrees in all cell lines, except A431 cells (Fig.
4a). The extent of EGFR downregulation was mostly evi-
Induction of apoptosis in cancer cells with wild-type EGFR or tyrosine kinase domain-mutated EGFR by cetuximab and gefitinib Figure 3
Induction of apoptosis in cancer cells with wild-type EGFR or tyrosine kinase domain-mutated EGFR by cetuximab and gefit-
inib. Cells from each line were left untreated or were treated with vehicle (DMSO), 5 nM cetuximab, or 0.5 µM gefitinib in a 
medium containing 0.5% FBS. After 16 hours of treatment, the cells were harvested and lysed for quantitative apoptosis meas-
urement by (a) an enzyme-linked immunosorbent assay, as described in the Methods section, and (b) Western blot analysis 
with anti-PARP antibodies. *P < 0.05, **P < 0.01 compared with corresponding controls.Molecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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dent in DiFi, H3255, and H1975 cells, indicating that the
extent of EGFR downregulation by cetuximab is unrelated
to the coding status of the EGFR sequence. Of interest,
gefitinib also led to decreased EGFR content in some cell
lines (e.g., DiFi and H3255), which was unexpected of a
TKI. The degree to which EGFR phosphorylation was
inhibited (relative to the controls) also varied. Under
comparable experimental doses and treatment condi-
tions, cetuximab was more effective than gefitinib in
inhibiting EGFR phosphorylation in HCC827, H3255,
and H1975 cells, but gefitinib was more effective than
cetuximab in DiFi, A431, and HCC2279 cells. In particu-
lar, cetuximab downregulated EGFR levels and inhibited
EGFR phosphorylation remarkably more than did gefit-
inib in H1975 cells; however, cetuximab was only slightly
more effective than gefitinib at inhibiting cell prolifera-
tion in H1975 cells (Fig. 2), suggesting that the levels of
EGFR downregulation or inhibition of phosphorylation
after cetuximab and gefitinib treatment are not consist-
ently correlated with positive responses in all cell lines.
ERK1/2, Akt, and STAT3 are three EGFR downstream sig-
nal mediators that are commonly evaluated after EGFR-
targeted therapy. Figure 4b shows the changes in their lev-
els of activation-specific phosphorylation after treatment
of the cells with cetuximab or gefitinib. Despite an overall
decrease in ERK1/2 and Akt phosphorylation levels after
either treatment in all cell lines except H1975, the degree
of ERK1/2 and Akt phosphorylation inhibition varied and
could not be quantitatively associated with the extent of
cellular responses to the treatment (Figs. 2 and 3). For
example, HCC827 cells were far more responsive than
HCC2279 cells to cetuximab- or gefitinib-induced growth
inhibition and apoptosis, but the patterns of change in
their ERK1/2 and Akt phosphorylation levels were similar.
Nevertheless, despite the fact that both gefitinib and
cetuximab induced apoptosis in DiFi and H3255 cells,
gefitinib inhibited ERK1/2 phosphorylation in DiFi cells
only modestly compared with cetuximab, but gefitinib
inhibited ERK1/2 in H3255 cells far stronger than did
cetuximab. Furthermore, gefitinib and cetuximab led to
similar levels of Akt phosphorylation inhibition in DiFi
cells, but gefitinib was far more effective than cetuximab
in H3255 cells. Taken together, these data indicate that
the inhibition of ERK and Akt phosphorylation by cetuxi-
mab or gefitinib is cell type-dependent.
Even more divergent results were found in the levels of
STAT3 phosphorylation after cetuximab and gefitinib
treatment: levels of Tyr705-phosphorylated STAT3, which
is regulated primarily via the JAK or Src kinase pathway
[26], were markedly increased in A431 and H3255 cells;
essentially unchanged or modestly increased in HCC827,
HCC2279, and H1975 cells; and decreased in DiFi cells.
Cell lines with an increased level of Tyr-705-phosphor-
ylated STAT3 after treatment had simultaneous decreases
in the levels of Ser-727-phosphorylated STAT3, another
important regulatory site that is regulated primarily by
ERK1/2 or mTOR kinase [27,28]. In DiFi cells, cetuximab
and gefitinib reduced phosphorylation at both sites but to
different degrees. In the remaining cell lines, the effects of
treatment on Tyr-705 phosphorylated and Ser-727 phos-
phorylated STAT3 levels were generally similar. An inves-
tigation into the possible mechanisms of increased Tyr-
705-phosphorylated STAT3 levels in some cell lines is
beyond the scope of the current study, but our results indi-
cate that changes in the levels of phosphorylated STAT3
certainly do not consistently reflect cellular responses to
cetuximab or gefitinib.
Downregulation of HIF-1α protein as a positive response 
marker to cetuximab and gefitinib
HIF-1α is a well-known transcription factor whose expres-
sion is regulated by growth factor- or oncogene-mediated
cell signaling via the phosphatidylinositol 3-kinase path-
way [15]. Figure 5 shows that, compared with untreated or
vehicle-treated cells, the pattern of changes in the levels of
HIF-1α protein generally mirrored that in the activation-
specific phosphorylation of Akt (Fig. 4b) but seems to be
more closely associated with the responses to cetuximab
and gefitinib treatment. All four cell lines that responded
well to cetuximab or gefitinib treatment (DiFi, A431,
HCC827, and H3255) had marked decreases in HIF-1α
levels. The patterns of these responses were generally sim-
ilar among the four cell lines, except that gefitinib induced
a higher level of HIF-1α inhibition than did cetuximab. In
contrast, in the remaining two cell lines that failed to
show an appreciable growth inhibition response to cetux-
imab and gefitinib treatment, the HIF-1α level did not
decrease. These results suggest that HIF-1α is a good indi-
cator of cellular response to EGFR-targeted therapy.
To provide experimental evidence supporting a critical
role of HIF-1α downregulation in mediating cellular
responses to EGFR-targeted therapy, we introduced a HIF-
1α mutant (HIF-1α/∆ODD) in A431 cells. In the HIF-1α/
∆ODD mutant, the oxygen-dependent degradation
(ODD) domain of HIF-1α was removed and therefore the
mutant became insensitive to VHL ubiquitin ligase-medi-
ated proteasomal degradation, rendering the expressed
truncated protein stable in normoxia [29]. After neomycin
selection, pooled A431 transfectant cells were obtained
and their response to cetuximab was compared with that
of control-vector transfected cells. Figure 6a shows that
the level of HIF-1α/∆ODD was minimally affected by
cetuximab, whereas the level of wild-type HIF-1α was
decreased in A431neo and, to a lesser degree, in A431/
HIF-1α/∆ODD cells. Importantly, A431/HIF-1α/∆ODD
cells remained as sensitive to cetuximab-induced inhibi-
tion of ERK and Akt as A431neo cells, as shown byMolecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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Effects of cetuximab and gefitinib treatment on the levels of total and phosphorylated EGFR and EGFR substrates in cell lines  with wild-type and mutated EGFR Figure 4
Effects of cetuximab and gefitinib treatment on the levels of total and phosphorylated EGFR and EGFR substrates in cell lines 
with wild-type and mutated EGFR. Cells from the indicated lines were simultaneously switched to a culture medium containing 
0.5% FBS and were either left untreated or treated with cetuximab (2 and 10 nM), vehicle, or gefitinib (0.1 and 0.5 µM) over-
night (16 hours). A master medium containing either cetuximab or gefitinib was used in all cell lines. After treatment, the cells 
were lysed, and equal amounts of cell lysates were subjected to Western blot analysis using antibodies directed against total 
and phosphorylated EGFR (Y-1068) (a) and antibodies directed against phosphorylated ERK, Akt, and STAT3 as indicated (b). 
The levels of β-actin and total ERK served as internal controls for equal protein loading in each lane in (a) and (b), respectively. 
The numeric values under each gel were derived from a densitometric analysis of the signals.Molecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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decreased levels of activation-specific phosphorylation in
the two molecules. However, the A431/HIF-1α/∆ODD
cells were considerably more resistant to cetuximab-
induced growth inhibition, as measured by an MTT assay
(Fig. 6b). Clonogenic survival assays showed that A431/
HIF-1α/∆ODD had markedly more surviving colonies
when cultured in the presence of cetuximab than did
untreated A431neo cells, indicating that constitutive
expression of HIF-1α can indeed render cells resistant to
cetuximab treatment (Fig. 6c).
Discussion
Identification of appropriate markers that dependably
mirror the responses of cancer cells to EGFR-targeted ther-
apy is a clinically important undertaking. In this study, we
used a group of cancer cell lines with either overexpressed
or tyrosine kinase domain-mutated (∆E746-A750 or
L858R) EGFR to assess their responsiveness to cetuximab
and gefitinib treatment and to evaluate HIF-1α as novel
molecular marker for the therapeutic responses of the can-
cer cells to EGFR-targeted therapy. We found that the post-
treatment decrease in the HIF-1α protein level better cor-
related with the cellular response than did the decreases in
the total or phosphorylated EGFR and phosphorylated
EGFR downstream substrate levels (ERK, Akt, and STAT3)
in cancer cells with wild-type or tyrosine kinas domain-
mutated EGFR. This observation was further confirmed by
experimental elevation of the HIF-1α level in the A431
cells, which conferred marked resistance to cetuximab
treatment on A431 cells, without affecting cellular sensi-
Downregulation of HIF-1α protein levels in cell lines with wild-type or mutated EGFR after treatment with cetuximab or gefit- inib Figure 5
Downregulation of HIF-1α protein levels in cell lines with wild-type or mutated EGFR after treatment with cetuximab or gefit-
inib. Cells from the indicated cell lines were treated with cetuximab or gefitinib overnight as described in Figure 4. After treat-
ment, the cells were lysed, and equal amounts of cell lysates were subjected to Western blot analysis using antibodies directed 
against HIF-1α, as indicated. The level of β-actin served as the internal control for equal protein loading in each lane. The 
numeric values shown under each gel were derived from a densitometric analysis of the signals.Molecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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tivity to cetuximab-induced inhibition of ERK and Akt
activation-specific phosphorylation levels.
It is rational to choose HIF-1α as a novel response marker
to EGFR-targeted therapy. First, functioning as an induci-
ble binding partner of an important transcription factor
regulating many genes involved in tumorigenesis and can-
cer progression, HIF-1α is an end downstream effector
molecule common to the ERK-, Akt-, and STAT3-mediated
signal transduction pathways. Because it represents a con-
vergent point of these pathways, HIF-1α is more critical
than ERK, Akt, or STAT3 alone in the relay of cell signaling
into the nucleus following activation of EGFR [15]. Sec-
ond, EGFR inhibitors are currently approved and being
tested only in solid tumors. Many solid tumors are
hypoxic and contain high levels of HIF-1α as a result of
increased protein stability; this makes detection of a post-
treatment decrease of HIF-1α relatively easy with histolog-
ical examination of biopsied tumor specimens or by
molecular imaging of HIF-1α level changes in the tumors
of patients [30,31]. Our data strongly suggest the value of
a retrospective review of the correlation of HIF-1α in
tumors with responses of the patients to the EGFR-tar-
geted therapies.
In our study, the cellular responses to treatment with
cetuximab and gefitinib are consistent with the previous
findings of others that mutations in the EGFR tyrosine
kinase domain renders the cancer cells sensitive to very
low doses of small-molecule TKIs, with the mutations
having no effect on cellular sensitivity to monoclonal
antibody treatment [24]. However, our data also suggest
Expression of HIF-1α/∆ODD mutant leads to cellular resistance to cetuximab without affecting cellular sensitivity to cetuxi- mab-induced inhibition of EGFR signaling Figure 6
Expression of HIF-1α/∆ODD mutant leads to cellular resistance to cetuximab without affecting cellular sensitivity to cetuxi-
mab-induced inhibition of EGFR signaling. (a) A431neo and A431/HIF-1α/∆ODD cells were treated as indicated for 16 hours 
(overnight). Cell lysates were prepared and subjected to Western blot analysis with the indicated antibodies. (b) Cells were 
left untreated or treated with the indicated concentrations of cetuximab in culture with 0.5% FBS for 5 days. Relative cell num-
bers were measured by the MTT assay and are presented as a percentage of the untreated control. (c) A431neo and A431/
HIF-1α/∆ODD cells (300 cells/dish) were cultured, with or without cetuximab (2 nM), for 9 days. After treatment, cells were 
fixed and the colonies were counted, as described in the Methods section.Molecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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that the mutation itself is not a sole determinant of apop-
tosis induction upon EGFR-targeted therapy, because our
data show that apoptosis can be induced in cells with
either wild-type EGFR (DiFi cells) or the mutated EGFRs
(H3255 and HCC827 cells) by either gefitinib or cetuxi-
mab treatment. Despite an enhanced sensitivity to low
doses of TKI, the maximal therapeutic responses to gefit-
inib and cetuximab in the EGFR-mutated cells were simi-
lar overall when the treatment timing and doses of either
agent were appropriate, leading to sufficient inhibition of
EGFR kinase activity. Two EGFR-mutated cell lines
(HCC827 and H3255) that underwent apoptosis upon
gefitinib treatment responded to cetuximab treatment
with similar ultimate results (apoptosis), and two other
EGFR-mutated cell lines (HCC2279 and H1975) that
responded poorly or moderately to gefitinib treatment
showed unfavorable responses to cetuximab as well. In
particular, H1975 cells contain a second mutation
(T790M) reported to be linked to gefitinib resistance [25],
but we found that these cells also responded poorly to
cetuximab.
It has been proposed that mutations in the tyrosine kinase
domain of EGFR cause repositioning of several critical res-
idues surrounding the ATP-binding cleft of the tyrosine
kinase domain; this repositioning stabilizes the interac-
tions between the ATP-binding site and reversible inhibi-
tors such as gefitinib [10,11]. Because of their strong
interaction, the mutated EGFR can be readily inhibited by
TKI with low doses that were usually insufficient to inhibit
wild-type EGFR. This speculation is consistent with
emerging evidence showing that irreversible EGFR inhibi-
tors decrease the receptor kinase more efficiently than do
reversible inhibitors [32]. There is an important caveat,
however: although the mutations in the EGFR tyrosine
kinase domain result in an enhanced cellular sensitivity to
TKI treatment, the mutated EGFR still requires a ligand for
receptor activation [10,11,33]. This requirement of ligand
binding suggests that EGFR-mutated cells and EGFR wild-
type cells should be equally susceptible to cetuximab-
mediated receptor blockade. Nevertheless, our data show
that cetuximab can indiscriminatingly downregulate
EGFR levels in cell lines with either wild-type or mutated
EGFR.
Of note, our results on the response of H3255 cells to
cetuximab differ from those of another recent study,
which reported that H3255 cells were substantially less
responsive to cetuximab than to gefitinib [24]. In our
study, this was true for only a short time period (6–8
hours) of exposure to cetuximab; cell death was not ini-
tially evident in cetuximab-treated cells, whereas gefitinib
induced massive cell death that was microscopically visi-
ble and measurable via biochemical assays. After the cells
had been cultured overnight, however, we found clear evi-
dence of apoptosis in cells treated with cetuximab, both in
the level of histone-associated DNA fragments in the cyto-
plasm and in the cleavage of PARP. By 72 hours, both
agents had markedly decreased H3255 cell survival. The
time course difference in inducing apoptosis between
cetuximab and gefitinib may be explained by the nature of
their different working mechanisms: EGFR inhibition
induced by cetuximab may require a longer time to effec-
tively block or downregulate EGFR than the time required
by gefitinib to shut down kinase activity through compe-
tition with ATP binding. In addition, cetuximab is highly
specific to EGFR, whereas TKIs are relatively less specific;
inhibition of additional targets besides EGFR by gefitinib
may also contribute to a faster cellular effect than that of
the monoclonal antibody.
Conclusion
Our data suggest that a decrease in HIF-1α levels is indic-
ative of positive responses to EGFR-targeted therapy of
cancer cells with either wild-type or tyrosine kinase
domain-mutated EGFR. Genetic aberrations causing an
exclusive dependence of cancer cells on the EGFR-medi-
ated cell signaling (i.e., oncogenic addiction), which may
be found in cancer cells with either wild-type or tyrosine
kinase domain-mutated EGFR, are likely the causes or the
molecular determinants of the apoptotic responses of
cells to EGFR-targeted therapy. The use of HIF-1α as an
indicator of tumor response to EGFR-targeted therapy




Cetuximab and gefitinib were gifts from ImClone Sys-
tems, Inc. (New York, NY, USA) and AstraZeneca (Wilm-
ington, DE, USA), respectively. All other materials were
purchased from Sigma-Aldrich (St. Louis, MO, USA)
unless otherwise specified.
Cell lines and culture
A431 human vulvar squamous carcinoma cells and DiFi
colorectal adenocarcinoma cells were described previ-
ously [34-37]. HCC827, HCC2279, H3255, and H1975
human NSCLC cell lines were kindly provided by Dr. John
Minna of The University of Texas Southwestern Medical
Center (Dallas, TX, USA) through Dr. Jonathan M. Kurie
of The University of Texas M. D. Anderson Cancer Center
(Houston, TX, USA). All cell lines were grown and main-
tained in Dulbecco's modified Eagle's medium or Ham's
F12 medium supplemented with 10% fetal bovine serum
(FBS), 2 mM glutamine, 100 U/mL penicillin, and 100 µg/
mL streptomycin and incubated in a humidified atmos-
phere (95% air and 5% CO2) at 37°C.Molecular Cancer 2007, 6:63 http://www.molecular-cancer.com/content/6/1/63
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RNA extraction, cDNA synthesis, polymerase chain 
reaction, and EGFR sequencing
Total RNA was extracted from the cell lines using a modi-
fied chloroform/phenol procedure (Trizol; Invitrogen-
Life Technologies, Gaithersburg, MD, USA). First-strand
cDNA of the intracellular domain of EGFR was generated
using reverse transcriptase (Roche Diagnostics Corp.,
Indianapolis, IN, USA) and amplified by polymerase
chain reaction (PCR) using the Expand high-fidelity PCR
system (Roche Diagnostics) with the following primer
pair: forward (2137–2157 bp), 5'-AAAAAGATCAAAGT-
GCTGGGC-3'; and reverse (3643–3625 bp), 5'-CCTC-
CGTGGTCATGCTCC-3'. PCR products were purified by
precipitation with alcohol, and sequences were analyzed
by an automated DNA sequence analyzer using the same
primers.
Western blot analysis and blotting antibodies
Cultured cells were harvested with a rubber scraper and
washed twice with cold phosphate-buffered saline. Cell
pellets were lysed and kept on ice for at least 10 minutes
with a buffer containing 50 mM Tris (pH 7.4), 150 mM
NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1 mM Na3VO4, 1
mM phenylmethylsulfonylfluoride, 25 µg/mL leupeptin,
and 25 µg/mL aprotinin. The lysates were cleared by cen-
trifugation, and the supernatants were collected. Equal
amounts of lysate protein were separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis, and
Western blot analyses were performed with various spe-
cific primary antibodies. The antibodies directed against
total and Y1068-phosphorylated EGFR, HER2, total and
S473-phosphorylated Akt, T202/Y204-phosphorylated
ERK, and PARP were obtained from Cell Signaling Tech-
nology, Inc. (Beverly, MA, USA). Antibodies directed
against ERK and HER3 were obtained from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Specific sig-
nals were visualized using an enhanced chemilumines-
cence detection kit (Amersham, Arlington Heights, IL,
USA).
Cell proliferation and survival assays
Time-dependent cell responses to treatments were deter-
mined by counting cells. After the various treatments, cells
were harvested by trypsinization and counted in a Coulter
counter. Dose-dependent cell responses to treatment were
determined by MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide] colorimetric assays. After
treatment, cells were incubated for 2 hours at 37°C in a
CO2 incubator with 10 mg/mL MTT (50 µL/well). The
cells were then lysed with a lysis buffer (500 µL/well) con-
taining 20% sodium dodecyl sulfate in dimethyl forma-
mide/H2O (1:1, v/v) (pH 4.7) at 37°C for at least 6 hours.
The relative survival of untreated and treated cells was
determined by measuring the optical density of cell lysates
at a wavelength of 570 nm. Cell viability was expressed as
a percentage and calculated as the optical density of the
treated cells relative to that of the corresponding control
or untreated cells.
Apoptosis assays
Apoptosis was measured by detecting proteolytic cleavage
of PARP using Western blot analysis and by quantifying
cytoplasmic levels of histone-associated DNA fragments
(mononucleosomes and oligonucleosomes) using an
enzyme-linked immunosorbent assay kit (Roche Diag-
nostics), as we previously reported [38,39].
HIF-1α construct and transfection
The pcDNA3 expression construct containing the HIF-1α/
∆ODD mutant was kindly provided by Dr. L. Eric Huang
(University of Utah School of Medicine, Salt Lake City,
UT, USA). Transient transfection of the construct was per-
formed with lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA), following the instructions provided by the
manufacturer (Roche Diagnostics).
Monolayer clonogenic assays
Exponentially growing cells were collected from monol-
ayer culture by trypsinization and plated at a low density.
Cells were allowed to adhere overnight prior to the addi-
tion of 2 nM cetuximab in 10% FBS culture medium for 9
days. Colonies were fixed in 1% crystal violet blue (w/v)
in 100% methanol for 30 minutes. Colonies estimated to
be larger than 50 cells were counted, and survival was cal-
culated relative to the number of untreated controls.
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